NAFLD-Nonalcoholic fatty liver disease
Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center
9
Morphological and metabolic determinants of nonalcoholic fatty liver disease in obese youth: a pilot study
6
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis
9
Original Article Study of the cut-off level of ALT and TG to predict the risk of nonalcoholic fatty liver disease in eastern China
7
Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
8
A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease
8
Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
8
Subclinical inflammation in relation to insulin resistance in prediabetic subjects with nonalcoholic fatty liver disease
8
Relationship between obesity, metabolic syndrome, and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan
8
Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Disease (CAD) in Patients with Angina Pectoris
5
Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk
9
Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)
6
Serum syndecan 1 and apolipoprotein a1 in patients with chronic hcv infection
7
Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital
7
Insulin Resistance in Egyptian Nonalcoholic Fatty Liver Disease patients
11
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
9
AYURVEDIC MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASES: A REVIEW .......
6
Role of bioactive fatty acids in nonalcoholic fatty liver disease
10
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
9
The Cellular Pathways of Liver Fibrosis in NASH
17